Page 76 - RESUME NOTE REMINDER

Δημοσιευτηκε σαν E-Poster (EP1127) DOI: 10.1530/endoabs.41.EP1127

Abstract

Aim: Thyroid cancer comprises the most common endocrine malignancy and a
variety of studies have examined the role of TSH as an independent risk factor for the
manifestation of differentiated thyroid cancer in otherwise benign thyroid disorders.

Objective of the current retrospective study was the assessment of a possible

relation between baseline serum TSH and thyroid microcarcinoma in a patient cohort
with non-toxic thyroid disorders and without preoperative cytological establishment
of thyroid cancer who underwent total thyroidectomy.

Patients and methods: Between 1 January 2005 and 1 March 2010, 186 patients (146
female/40 male) underwent total thyroidectomy because of nodular thyroid disease

in our Department. Thyroid specimens were histopathologically examined at the
University Pathology Department for the establishment of the final diagnosis of

benignity or malignancy. Median values of preoperative serum TSH were estimated
in both dignity groups and the results were compared regarding preoperative
diagnosis.

Results: Thirty-two patients (17.2%) were diagnosed with microcarcinoma (rate
females: males 2.2:1), while 154 patients (82.8%) were free of malignancy. The

median value of basal serum TSH was higher in the malignancy group and without
statistical significance (1.02 vs 0.80; P value 0.293). Regarding patients with solitary

thyroid nodule TSH presented higher in the benignity cohort (1.3 vs 0.83; P value
0.289), whereas in patients with non-toxic multinodular goiter TSH was higher in the

malignancy group but marginally without statistical significance compared to the
benignity group (1.16 vs 0.75; P value 0.05) Conclusions: In the present study, basal

serum TSH did not feature an independent risk predictor for the development of
thyroid microcarcinoma in non-toxic nodular thyroid diseases. A borderline
non¬significant trend of higher TSH was shown however in non-toxic multinodular

goiter harbouring malignancy. Further studies evaluating the role of TSH in thyroid

cancer are required.

16. Thyroid autoimmunity and risk of incidental thyroid microcarcinoma in non-toxic
nodular thyroid diseases

76